Last reviewed · How we verify

levobupivacaine, clonidine

University Hospital, Clermont-Ferrand · FDA-approved active Small molecule Quality 5/100

Levobupivacaine, in combination with clonidine, is a marketed anesthetic agent developed by University Hospital, Clermont-Ferrand. The key composition patent for this drug is set to expire in 2028, providing a clear period of exclusivity and potential revenue protection. The primary risk is the lack of reported key trial results and revenue data, which may limit the drug's market visibility and competitive positioning.

At a glance

Generic namelevobupivacaine, clonidine
SponsorUniversity Hospital, Clermont-Ferrand
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: